A Look Ahead at Rheumatology in 2024
April 29, 2024
-
2 min
5 Key Takeaways
-
1
Dr. Maheswaranathan reflected on rheumatology developments in 2023 and anticipated positive changes for the field in 202
-
2
In 2023, steroid-sparing therapies for rheumatic diseases, the approval of sarilumab for patients with refractory polymyalgia rheumatica, and the expansion of digital medical education were explored.
-
3
Dr. Maheswaranathan highlighted the limited therapeutic options for lupus patients and the negative impact of social determinants of health on disease activity, treatment effectiveness, and health outcomes.
-
4
Ongoing clinical trials examining novel therapies for lupus, the advancement and utilization of telemedicine and artificial intelligence, and the analysis of targeted therapies in upcoming clinical trials may lead to positive changes in rheumatology in 202
-
5
Dr. Maheswaranathan concluded that the field may see new explorations and discoveries in 2024 that challenge the current understanding of rheumatic disease treatment.
Dr. Mithu Maheswaranathan, a rheumatologist at Duke University Health, reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024. In 2023, steroid-sparing therapies for rheumatic diseases, the approval of sarilumab for patients with refractory polymyalgia rheumatica, and the expansion of digital medical education were explored. Dr. Maheswaranathan noted the limited therapeutic options for lupus patients and highlighted the negative impact of social determinants of health on disease activity, treatment effectiveness, and health outcomes. Looking ahead, ongoing clinical trials examining novel therapies for lupus, the advancement and utilization of telemedicine and artificial intelligence, and the analysis of targeted therapies in upcoming clinical trials may lead to positive changes in rheumatology in 2024.
Listen Tab content
